earnings
confidence medium
sentiment negative
materiality 0.65
Tonix reports preliminary Q1 net loss $40.8M, cash $185.5M, revenue $6.9M
Tonix Pharmaceuticals Holding Corp.
2026-Q1 EPS
reported -$2.93
vs consensus -$2.48
▼ miss
(-18.0%)
- Net loss for Q1 2026 was ~$40.8M, up from $16.8M in Q1 2025; revenue rose to $6.9M from $2.4M, led by TONMYA ($3.7M).
- Cash and equivalents at March 31, 2026: $185.5M; common shares outstanding as of April 30, 2026: 15,540,801.
- Net cash used in operations was $40.2M in Q1 2026 vs $16.6M in Q1 2025; capex was $1.7M vs $6,000.
- Raised $17.4M net from equity offerings in Q2 2026; cash runway expected into Q2 2027.
- Preliminary results subject to revision; final Q1 2026 10-Q expected on or about May 11, 2026.